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ABSTRACT: NMR-based metabolomics has shown considerable
promise in disease diagnosis and biomarker discovery because it allows
one to nondestructively identify and quantify large numbers of novel
metabolite biomarkers in both biofluids and tissues. Precise metabolite
quantification is a prerequisite to move any chemical biomarker or
biomarker panel from the lab to the clinic. Among the biofluids
commonly used for disease diagnosis and prognosis, urine has several
advantages. It is abundant, sterile, and easily obtained, needs little
sample preparation, and does not require invasive medical procedures
for collection. Furthermore, urine captures and concentrates many
“unwanted” or “undesirable” compounds throughout the body, pro-
viding a rich source of potentially useful disease biomarkers; however,
incredible variation in urine chemical concentrations makes analysis of
urine and identification of useful urinary biomarkers by NMR chal-
lenging. We discuss a number of the most significant issues regarding NMR-based urinary metabolomics with specific emphasis
on metabolite quantification for disease biomarker applications and propose data collection and instrumental recommendations
regarding NMR pulse sequences, acceptable acquisition parameter ranges, relaxation effects on quantitation, proper handling of
instrumental differences, sample preparation, and biomarker assessment.
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Metabolomics (also known as metabonomics) is the study of
global metabolite profiles in biological samples such as biofluids,
cell extracts, and tissues. Metabolomics can be integrated with
other omics sciences such as genomics, transcriptomics, and
proteomics to facilitate a more complete understanding of
global biological systems. Metabolite concentrations and
perturbations represent a snapshot of the metabolic dynamic
that reflect the response of living systems to environmental
factors, pathophysiological stimuli, or genetic modification.
To characterize the vast array of metabolites found in any
given biosample, metabolomics researchers must utilize a wide
range analytical platforms including high-performance liquid
chromatography (HPLC),1 liquid chromatography with mass
spectrometry (LC−MS),2 gas chromatography with mass
spectrometry (GC−MS),2a,b,3 tandem mass spectrometry,4
and NMR spectroscopy.5 Each technique has its own advan-
tages and disadvantages, and the choice of a given analytical
platform often depends on the focus of the study and the
samples.6
The use of NMR in metabolomics is particularly appealing
to many researchers because of its nondestructive, quantitative
nature and its ability to identify novel compounds via their unique
spectral patterns.7 InNMR-basedmetabolomics, biological fluids
such as serum, plasma, urine, saliva,8 cerebrospinal fluid,9
amniotic fluid,10 synovial fluid,11 exhaled breath condensate,12
cell extracts,13 and tissue extracts7g,14 have all proven to be
particularly amenable to NMR analysis. Urine, in particular, is a
very appealing biofluid for analysis because it is abundant, can be
collected noninvasively, and is particularly rich in terms of its
chemical diversity. Consequently, urine offers significant
opportunities for data mining, data modeling, and biomarker
discovery, particularly with respect to human health and
disease.15 Furthermore, urine exhibits a strong phenotypic or
metabotypic stability,16 which strengthens its potential for
biomedical research and clinical utility.
Urine is composed primarily of small hydrophilic molecules
such as sugars, organic acids, amino acids, soluble lipids, organic
amines, and so on, along with inorganic salts that are small
enough to have successfully passed through the body’s reticu-
loendothelial filtration system. While the noninvasive collection
of urine is advantageous for manymetabolomics applications, the
major spectroscopic challenge associated with analyzing urine by
NMR is the tremendous variation in its chemical concentrations.
There are a number of factors, including sample collection and
processing, as well as data acquisition and processing parameters,
that need to be considered to enable accurate and precise
quantitation of urinary metabolites by NMR-based metabolo-
mics. Metabolic profiling of urine gives a time-averaged
representation of an individual’s recent (typically within 24 h)
homeostatic condition. Some metabolites may associate with
individual’s physiological or pathological state, whereas others
may associate with an individual’s genotype, environmental
exposures, dietary habits, or drug intake17 as well as the time
(season, hour of the day) of collection. Indeed, one of the most
significant unresolved issues in urinary metabolomics lies in the
remarkable variance in urinary excretion volumes and sub-
sequent variations in metabolite concentrations.18 As such, it is
critical that in quantitative metabolomics the inter- and
intraindividual metabolite variance within the normal/control
group be properly identified, defined,18 and as much as possible
minimized. This may be facilitated by requiring a 12 h fast
prior to urine collection or restricting the consumption of
supplemental protein performance enhancing food, such as
protein shakes, prior to any sample collection.19 Even with these
controls in place, the variance in urine metabolite concentrations
is still quite significant.
In light of these challenges, a coherent standard protocol is
particularly important for the analysis of urinary biomarkers.
To ensure robust and accurate quantification of potential urinary
biomarkers by NMR, each step of the analytical protocol must be
carefully performed and evaluated. This includes appropriate
consideration for the context of the chosen application. For
example, in nutritional intervention studies, it is important that a
standardized diet is introduced to participants prior to the
intervention and subsequent sample collection to minimize
dietary effects confounding the results. Specifically, sample
collection, preservation, preparation as well as instrumental
optimization, NMR pulse sequence selection, and choice of
acquisition parameters, data-processing parameters, peak/
metabolite identification confidence, and final reporting results
must be undertaken with a high level of consistency and an
appropriate degree of scientific rigor to ensure the validity of the
results. This process is not entirely straightforward, and much
research has been devoted to refining, testing, and optimizing
each step of the NMR analytical and data processing
protocols.7d,20 Indeed, more than 70 papers have been published
on the subject since 1990, with one of the most widely cited of
these being the publication by Beckonert et al.20b While
advocating the need for standardized protocols in metabolomic
applications (i.e., theMetabolomics Standards Initiative),21 these
authors also noted that it may be “detrimental to the exploratory
nature of the subject to allow only “validated” or “approved”
procedures to be used in experimental metabolism studies.”
This acknowledges the importance of further research and
improved methodologies for sample handling, data acquisition,
and data analysis.
In a previous Review22 we proposed several recommenda-
tions regarding the standardization of the experimental
conditions for using urine in NMR-based metabolomic studies.
We highlighted the effects of diet, sample collection time
(of day), age, gender, gut microflora, individual metabotypes,
physical activity, subject selection, sample storage, salt, and
pH effects as well as acquisition temperature with regard to
urine metabolite composition and concentrations. We also
provided recommendations regarding ethical guidelines for
sample acquisition, the establishment of written SOPs, the
selection of containers/consumables, patient/sample selection
protocols, sample collection handling methods (centrifugation,
additives, storage protocols), sample transfer methods, sample
pH, chemical shift referencing, minimum sample numbers,
sample randomization, magnetic field strength, optimal NMR
pulse sequences, acquisition temperature, and results or reporting
standards.
In this Review, we will discuss the pertinent issues regarding
NMR-based urinary metabolomics with a specific emphasis on
quantification for disease biomarker applications. We first review
and discuss some of the key issues relating to (1) biomarker
assessment, (2) urinary biomarkers and the need for metabolite
quantification, (3) metabolite quantification methods for NMR,
(4) examples of NMR-derived biomarkers, and (5) concen-
tration normalization methods. Consensus recommendations
will then be made regarding: concentration normalization,
suitable NMR pulse sequences, acceptable parameter ranges, the
effects of relaxation on quantitation, and the utility of data
acquired on different instruments
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2. BIOMARKERS AND BIOMARKER ASSESSMENT
A biomarker is a measurable substance in a biofluid or biological
tissue that can be used as an indicator of some biological
perturbation caused by a disease, a change in biological state, or
an environmental exposure. Biomarkers may be used for disease
diagnosis, prognosis, prediction, or monitoring as well as for
measuring biological responses from various drug, toxin, or
environmental exposures. Biomarkers have a wide range and may
include chemicals, metabolites, genes/mutations, RNA tran-
scripts, proteins, cell counts or cell types, karyotypes, or just
about any other detectable substance or measurable biological
feature. As a general rule, a single biomarker often corresponds
to a single medical test, with a threshold value (concentration
or number) being used to distinguish between healthy and dis-
eased states.
2.1. Biomarker Sensitivity and Specificity
The performance of a biomarker is typically evaluated by its
sensitivity and specificity. Sensitivity relates to the biomarker’s
ability to identify positive results and specificity relates to the
biomarker’s ability to identify negative results. More specifically,
sensitivity can be defined as “the proportion of patients who
are known to have the disease who test positive for it”, while
specificity can be defined as “the proportion of patients that
are known not to have the disease who will test negative.”
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In commonmedical practice, sensitivity is generally not sufficient
to assess the diagnostic performance of a test where the test has
no negative predictions (from a theoretical point of view, 100%
sensitivity). Therefore, both sensitivity and specificity should be
examined together and reported in disease diagnostic studies.
Figure 1 demonstrates the assessment of biomarker perform-
ance, in the context of a biomarker’s ability to differentiate
between diseased and healthy subjects.23 Table 1 summarizes the
relationship between positive and negative test outcomes and of
true/false positives and negatives.
Simultaneous measurement of both sensitivity and specificity
with respect to different separation threshold values is often best
illustrated using a receiver operating characteristic (ROC) curve.
An ROC curve shows how the sensitivity and specificity change
as the classification decision boundary is varied across the range
of available biomarker scores. An ROC curve is not dependent on
the prevalence of a given outcome, and because it shows the
performance of a biomarker test over the complete range of
possible decision boundaries, it allows the optimal specificity or
sensitivity to be determined posthoc. ROC curves are often
summarized into a single metric known as the “area under the
curve” (AUC). For a perfect biomarker test, the AUC is 1.0. An
AUC of 0.5 is equivalent to randomly classifying subjects (i.e., the
classifier is of no practical utility). A rough guide for assessing
the utility of a biomarker based on its AUC is as follows: 0.9 to
1.0 = excellent; 0.8 to 0.9 = good to very good; 0.7 to 0.8 = fair;
0.6 to 0.7 = poor; 0.5 to 0.6 = fail. ROC curve analysis and using
ROC-AUC is widely considered to be the most objective and
statistically valid method for biomarker performance evaluation.
A much more detailed review of ROC analysis along with general
recommendations for biomarker quantification and statistical
strategies for multibiomarker models is provided elsewhere.23
3. BIOMARKERS AND METABOLITE QUANTIFICATION
Metabolites and metabolite concentrations can be particularly
sensitive to modest physiological or subtle genetic perturbations.
Observed changes to urine have historically been accredited to
attempts to diagnose ailments as far back as the ancient Greek
physician Hippocrates (400 BC) and the Arabian/Persian
alchemist Avicenna (11th century). Indeed, as Sir Archibald
Garrod (the founder of modern clinical chemistry) noted in
1908, changes in metabolite concentrations often start before the
onset of clinical symptoms.24 This simple fact has served as the
basis to the development of more than 180 different chemical or
metabolite biomarker tests that are commonly used today
(https://labtestsonline.org). Indeed, there are more approved
metabolite- or chemical-based clinical tests than approved genetic,
protein, or karyotype tests (https://labtestsonline.org). While
most clinical tests are blood-based, an increasing number of
clinical assays that use urine currently exist. The very first clinical
assay (and the first genetic disease test) was designed for
detecting homogentisic acid among individuals with a rare inborn
error of metabolism called alkaptonuria.24 Among the most
commonly used metabolite tests today are urinary glucose tests
for monitoring diabetes,25 24 h urinary creatinine tests to
measure kidney function,26 urinary cortisol tests to diagnose
Cushing’s or Addison’s disease, urinary nitrite tests to detect
Figure 1. Demonstration of the biomarker prediction test with two
Gaussian curves indicating the distributions of measured values, with
positive cases on the right side and negative cases on the left. The dashed
lines indicate the cutoff threshold of hypothetical biomarker
concentration that can be used to separate positive from negative
tests. The overlap between the biomarker concentrations of the two
populations represents the misclassification ratio between the left-hand
side of the positive cases and the right-hand side of the negative cases.
TP, the number of true positives; TN, the number of true negatives; FP,
the number of false positives; FN, the number of false negatives,
respectively.23
Table 1. Relationship between Terms of Positive andNegative
Test Outcomes
condition positive condition negative
positive test outcome true positive false positive
negative test outcome false negative true negative
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bacterial infections, and urinary bilirubin tests to assess liver
function (Table 2).
Almost all approved clinical chemistry tests, whether they
measure chemical or protein biomarkers, are required to be
quantitative or at least semiquantitative (via some ratio
measurement). This requirement has allowed universal reference
values for different ages and genders to be developed and applied
for routine medical diagnoses. In many cases physicians and
clinical chemists are required to know or memorize threshold
values for a large number of medically important metabolites and
proteins. Absolute quantification not only gives physicians useful
reference or decision-making thresholds but also ensures
consistency and reproducibility from instrument to instrument,
lab to lab, city to city, and country to country. As previously
stated, the issue of quantification has turned out to be an Achilles
heel for many biomarker tests developed using “omics”
platforms.15b,27 This is because proteomic, transcriptomic, and
even most metabolomic assays were not originally designed
with comparative quantitation in mind, nor were they designed
to be compared accurately and precisely between different
instrumental platforms.
However, there is now a growing shift in the “omics”
community toward developing quantitative proteomic and
quantitative metabolomic assays5g,23,28 with a long-term goal of
using these quantitative assays for biomarker discovery, develop-
ment, and clinical translation.23 The need for quantification,
either relative or absolute, is particularly acute for metabolite-
based urine analysis where individual metabolite concentration
values can vary by a factor of 10 or more due to dilution, gender,
diet, or diurnal effects.29 As a result there have been a number
of papers, NMR-specific software tools (Chenomx, AMIX,
Batman,30 Bayesil,31 etc.), as well as a number of commercial
kits that have been developed (such as the BioCrates kit for
mass spectrometers) to perform absolute metabolite quantifi-
cation. Methods to facilitate urinary metabolite quantification,
with a specific focus on NMR, are briefly reviewed in the next
section.
4. QUANTITATION OF METABOLITES BY NMR
NMR spectroscopy is a powerful analytical approach for both
identification and quantification of analytes with superior
advantages, such as being nondestructive, highly reproducible,
and, most importantly, requiring minimal sample preparation.32
Indeed, NMR is inherently a quantitative technique as the
intensity of an NMR signal is proportional to the concentration
of detectable (usually 1H) nuclei in the receiver coil.33 The 1D
1H NMR spectra of urine samples are highly complex, with
thousands of distinct signals visible in a single spectrum.
Consequently, signal overlap and signal distortions from nearby
(strong) peaks are often evident even in 1D 1H NMR spectra
collected at 800 MHz and above. Over the past two decades,
several methods had been proposed or developed to address
these issues. In particular, an exhaustive technical review on this
subject has recently been published by P. Giraudeau.34 This
paper nicely summarizes the strengths and weaknesses of various
2D NMR methods, for example, 2D J-resolved, COSY, TOCSY,
2D INEPT, HSQC, HMBC, and so on, with regard to resolution
in the second dimension and with respect to compound
identification and quantification in complex mixtures. Common
shortcomings identified for all (conventional) 2DNMRmethods
were the lack of sensitivity, the lack of speed, and the difficulties
in reproducible quantitation compared to 1D NMR; however,
this paper also highlighted several novel 2D NMR methods or
data-processing techniques that appear to solve or at least
address some of these issues. For instance, 2D 1H INAD-
EQUATE with sparse sampling/nonlinear sampling (NLS) as
proposed by Hyberts et al.35 seems to be very promising for
characterizing and quantifying low abundance metabolites. More
recently, another approach has been proposed,36 wherein three
different collection and processing techniques were combined,
including J-compensated 2D HSQC, NLS, and forward entropy
(FM) reconstruction. This combination resulted in a 22-fold
reduction in NMR recording time (relative to a conventional
HSQC spectrum) while at the same time yielding precise
metabolite quantitation in both native and lyophilized urine
samples. The authors report a lower limit of detection of “tens of
micromolar”; however, these types of experiments are not
straightforward, and significant prior knowledge about the
sample and expected spectral windows is needed to properly
implement the method. Furthermore, while these approaches
are promising, they have yet to be implemented in a real,
nontargeted metabolomic study nor have they been compre-
hensively evaluated and validated. Ultrafast 2D NMR spectros-
copy37 is yet another promising method; however, this approach
requires sophistication in pulse field gradient performance and
specific processing software, presently not available on most
commercially available NMR spectrometers. Nevertheless, given
its speed, resolution, and sensitivity advantages over fast
heteronuclear NMR and even 1D homonuclear NMR methods,
this approach may soon become the method of choice for
identifying and quantifying low abundance metabolites in urine
samples.
Unlike MS-based quantitative methods, which usually require
expensive isotopically labeled standards and time-consuming
Table 2. Examples of Urinary Biomarkers of Disease
Discovered Using NMR-Based Metabolomics in Human
Studies
condition comparison biomarkers reference
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chromatographic separations, NMR spectroscopy offers the
possibility of quantifying many metabolites simultaneously
without the need for any prior chromatographic separation;
however, accurately and reproducibly quantifying NMR signals
from different instruments at different field strengths and using
different pulse sequences or pulse widths and delay times is often
challenging. Indeed, despite a steady increase in the number of
publications arising from NMR-based metabolomics focused on
diagnostic biomarkers, only a few of these report quantified
metabolite levels.23,29a,38 This paucity of quantitative data could
be due to the fact that metabolite quantification is both
instrumentally challenging and manually intensive work.
In terms of instrumental issues, the greatest challenge in
NMR-based quantification lies in consistency and reproducibility.
To obtain consistent and reliable results, identical NMR tubes
must be used as well as identical instrument parameters including
temperature, chemical shift referencing, tuning, shimming,
magnetic field drift compensation/lock, pulse sequences, water
suppression methods, acquisition times, and data-processing
parameters (Table 3). These conditions must be strictly adhered
to from sample to sample. This not only allows for rigorous
quality assurance but also allows robust intralaboratory and
interlaboratory comparison. Variations in the ionic strength of
different samples can have dramatic effects on the ability to tune
and match the spectrometer (assuming the probe range is
sufficient), leading to profoundly different pulse widths or
spectrometer responses. Specifically, what are assumed to be
infinitely short “on-resonance” pulses become ineffective (much
less than 90°) and contain larger and larger off-resonance pulse
effects (evolution). This can have dramatic consequences
regarding relaxation of the NMR signal in-between data
acquisitions. In addition, some instrumental effects (e.g., field
instability, temperature variations, incorrect referencing) can
cause chemical shift changes. Recently, Sokolenko et al. evaluated
the sources of quantification variability in NMR and determined
that such seemingly mundane issues as sample insertion methods
or shimming protocols as well as the choice of NMR pulse
sequence could lead to significant differences in the resulting
metabolite identification and quantification.39 It has also been
shown that the data acquisition parameters, spectral processing
parameters, and the choice of water suppression method can also
substantially affect metabolite quantification results.40
As a general rule, a single excitation pulse sequence with a
relatively low-power water presaturation is the default method
Table 3. Experimental Conditions for Precise Quantitation of Urine Samples Using NMR Spectroscopy
sample
preparation parameters and recommended values comments
sampling overnight fasting urine collection ensures more stable homeostatic concentrations of metabolites
mid stream urine collection avoids unwanted contamination from urinary tract
collecting urine sample in labeled tube containing sodium azide (NaN3) to stop bacterial growth in samples; final concentration of
0.05% wt/vol
store immediately in to −40 to −80 °C until NMR experiments are performed helps arrest metabolic activities and sample degradation
sample
processing
centrifugation/filtration centrifuge at 1000 rpm to remove the turbidity from unwanted
particulates, or filter using 0.22 μ filter to remove any
macromolecular content in the sample
phosphate buffer phosphate buffer helps in avoid chemical shift drift that occurs due
to pH variations
internal reference standard; e.g., TSP or DSS in protein/lipid free urine sample, TSP and DSS are a good choices
as internal standards for quantification and normalization
use of deuterated EDTA only recommended when variation of ionic concentration urine is




one-dimensional gradient NOESY with water presaturation experiment.
time domain points (TD): 64K Increased resolution
line broadening (lb): 0.1−0.5 Hz
relaxation delay >5.0 s relaxation delay depends on longitudinal relaxation time (T1) of
metabolite resonances; it should be five times T1 for absolute
quantitation or matched to the T1 of the reference spectra used
for deconvolution.
acquisition time: 2.5 s increased resolution
spectral width (sw): 12 ppm
number of scan (ns): 64 for desired S/N, more are required for diluted samples
dummy scan (ds): 8 to achieve steady state prior to acquisition
excitation pulse: 90 deg shorter pulse widths can be used for single pulse NMR analysis
receiver gain (rg): optimal either a constant RG for all or auto optimized for every sample
mixing time (tm): pulse sequence requirements for NOESY; minor loss in signal
intensity due to transverse relaxation100 ms for standard experiment
10 ms for gradient experiment
sample temperature: 300 K kept constant throughout the study
shimming, tune, and match: for every sample increased accuracy, precision, and reproducibility
processing
parameters
windowing: exponential window function with line broadening of 0.3−1.0 Hz
zero filling: a factor of 2 of TD increased resolution
phase correction: manual phasing is preferred optimal for accurate integration of peaks area
baseline correction: automatic/manual increased accuracy of peak integration
chemical shift referencing both TSP and DSS can be used for chemical shift referencing
(δ 0.0), although DSS is the IUPAC standard
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for performing quantitative metabolite analysis of biofluids and
biological extracts. Historically, quantitation in NMR required
the use of long pulse delays to allow signals to fully recover, but
more recently the use of a low flip angle (i.e., ≪90°) to
accommodate faster signal recovery along with suitable signal
correction methods has allowed much more rapid data
acquisition.41 For most biological samples, there is a substantial
amount of water present, so strong solvent suppression must be
employed to obtain good metabolite signals. Therefore, a 1D
NOESY pulse sequence with water presaturation (see ref 42 and
references therein), excitation sculpting,43 or WATERGATE
solvent suppression44 is preferred. Because of solute/solvent
hydrogen exchange, the presaturation sequence itself can
dramatically alter quantitation results. Specifically, the exchange-
able proton signals from urea and other water exchangeable
solutes are often suppressed by presaturation, making their
quantification difficult or inconsistent. While more complex
solvent suppression schemes like PURGE,45 excitation sculpting,
or variations of WATERGATE46 are potentially better choices
for metabolite quantification, these pulse sequences all have
auxiliary regions of signal suppression, which makes them more
difficult to optimize and harder to use. This added complexity
can also affect interlab and intralab consistency or reproduci-
bility. Pulsed field gradient (PFG) versions of NMR pulse
sequences (e.g., 1D NOESY pulse sequence) are available, but
these may lead to problems with quantification due to both lock
instability and gradient ring down periods.47 These problems
manifest as peak distortions (i.e., semidispersive line shape) to
the internal chemical shift and quantitation reference (such as
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)). For these
reasons, gradient pulse sequences, despite their advantages,48 are
not recommended.
In terms of spectral analysis, metabolite quantification requires
meticulous consistency and considerable attention to detail.
Prior to spectral collection, each biofluid sample must be
“spiked” with an exact amount of a known quantification
standard (usually a chemical shift reference standard such as
tetramethylsilane (TMS) for organic solvents or trimethylsilyl
propanoic acid (TSP) and 4,4-dimethyl-4-silapentane-1-sulfonic
acid (DSS) for water-based experiments).49 Once the NMR
spectra have been collected, the data must be properly phased
and baseline-corrected, and any residual interfering solvent
signals must be digitally filtered. Then, individual “sentinel”
peaks corresponding to the specific compounds must be
identified, and the peak area(s) carefully integrated.50 This
identification and quantification step (also called spectral
deconvolution) can be done manually, semiautomatically, or
automatically (vide infra). The concentration of a given
metabolite can be directly calculated from the spiked standard












where [M] is the metabolite molar concentration, [Std] is the
spiked standard’s known molar concentration, Im is the
metabolite intensity, Is is the intensity of the spiked standard’s
peak, Nm is the number of nuclei contributing to the metabolite
peak, and Ns is the number of nuclei contributing to the spiked
standard’s peak. In some cases it is not necessary to use an
internal standard to quantify metabolites but rather one may use
an external reference or an electronic reference signal,59,60 or
even the solvent resonances.52
A key challenge with quantifying metabolites in biological
samples, and especially in urine, is the considerable degree of
spectral overlap seen in 1D 1H NMR spectra. For example, urine
NMR spectra typically consist of >2000 detectable peaks
corresponding to >200 detectable compounds.53 The positions
and shapes of these peaks can vary with pH, temperature, salt
concentrations, magnetic field strength, sample stability, and
homogeneity. In addition, common 1H−1H dipolar or
quadrupolar (e.g., 14N−1H) couplings further complicate the
observations. Consequently, it is very difficult for even a trained
individual to identify a single set of “sentinel” peaks that can be
unambiguously identified and properly integrated for any given
urine sample. To assist with this peak identification and
metabolite identification process it is possible to use several
approaches. One approach is spectral simplification through
statistical analysis or chemometric analysis using spectral
binning/alignment and statistical total correlation spectroscopy
(STOCSY).54 These methods statistically align and compare the
NMR spectra between two groups (diseased and healthy), and
the most significantly different peaks are then identified.
This leads to a reduction in the number of peaks that need to
be analyzed or identified. A disadvantage of this approach is
that it can lead to problems in compound identification and
quantification, as the spectra have been extensively averaged or
“warped” as part of the statistical processing.54
Another approach involves identifying and quantifying as
many compounds as possible prior to determining any statistical
differences between groups. This leaves the NMR spectra in a
relatively pristine state so that compound identification and
quantification is easier and more accurate; however, the process
is time-consuming, as dozens of compounds and hundreds of
peaks must be identified and quantified through a process known
as spectral deconvolution.54a Several companies have developed
spectral deconvolution tools and software (e.g., Chenomx
NMRSuite from Chenomx, Inc.; AMIX from Bruker, Inc.;
MnovaScreen from Mestralab Research; CRAFT or Complete
Reduction to Amplitude Frequency Table from Agilent) that
makes this process easier. These packages include carefully
collected reference NMR spectra of hundreds of common meta-
bolites at different field strengths and pH values. These programs
and their corresponding libraries can allow 50−75 compounds to
be manually identified or quantified from urine spectra in about
1−4 h; however, this process must be performed by well-trained
individuals. The requirements of manual phasing, manual
baseline correction, manual solvent removal, and manual spectral
deconvolution often mean that quantification inconsistencies
and even compound identification errors can be introduced.
For example, one published study looked into these issues of
consistency and reproducibility39 and found compound
quantification by some of these methods is only accurate to
within 15%. More recently several groups have attempted to
develop fully automated methods that remove any human
variability in spectral processing and compound identifica-
tion.30b,55 These methods appear to be very promising, especially
for simpler biofluids such as serum, saliva, or cerebrospinal fluid,
but they have yet to be shown to be effective for biofluids as
complex as urine.
Sample-to-Sample Normalization
The large differences in metabolite concentrations observed in
different urine samples can complicate comparisons between
samples and may lead to false conclusions. Thus, normalizing
NMR spectra is a critical step for eliminating systematic errors.
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In addition to normalizing concentrations relative to creatinine
(which is commonly done in clinical practice), several other
normalization methods have been developed, including total
integral intensity (usually the total spectral area). This is one of
the most commonly used methods in NMR.56 Other methods
have been proposed as an alternative to the total intensity
method, including probabilistic quotient normalization (PQN)57
and histogrammatching (HM),58 which effectively make the data
more suitable to identifying potential metabolic biomarkers for
disease.
Normalization can be problematic due to the potential
influence that the method might have on compound identi-
fication or quantification. While one would hope that compound
identification is unaffected (see later), the relative proportions
certainly might. This assumes that normalization would occur
only on the quantitation of unambiguous peaks (i.e., no overlap)
and would apply to all such positively identified metabolites.
This might seem obvious, but it needs to be explicitly stated as
normalization can also refer to frequency-dependent compensa-
tion for NMR pulse sequence effects, for example, T1-dependent
changes. Any changes to the NMR pulse sequence or parameters
will perturb peak heights. Any compensation for pulse sequence
differences would also affect the peak ratios for atoms in the same
molecule as well as the overall metabolite quantitation. For
example, a compensation for different presaturation power levels
would correct amplitudes differently close to the carrier position
versus the edges of the spectra. A compound containing
resonances both close to and far from the water resonance
would then have an intramolecular integration ratio that would
not make sense and could have its identification changed or
moved to an ambiguous/unassigned grouping.
This is not a problem unique to NMR. Mass spectrometry
(MS) has been dealing with this issue for years. In MS, control
samples are introduced into the sample queue to compensate for
changes in the chromatographic steps and equipment necessary
to separate metabolites. Specifically, quality control samples are
submitted at regular intervals or samples are combined and run as
reference samples for comparison. Interestingly, in NMR, the use
of control or calibration samples is not regularly done. While
chromatographic columns are not normally used in NMR,
batched samples run on robotic sample handling systems must
often sit for lengthy periods of time (hours) prior to loading and
spectral acquisition. Control samples placed at the beginning,
middle, and end of a long sample-loading run would therefore
reveal any potential degradation/storage/handling problems or
(less likely) changes occurring to the spectrometer/console/
probe.59 Compared with the extensive efforts used in quality
control for MS, the use of quality control for normalization in
NMR is, in our opinion, still under-developed.
5. EXAMPLES OF POTENTIAL NMR-DERIVED URINARY
BIOMARKERS
There is an abundance of literature linking urinary biomarkers
with human disease states.7e,15b,60 The analytical approaches
used to collect these data are certainly diverse, and this diversity
serves to demonstrate the complexity associated with developing
standardized approaches for urinary biomarker quantification.
Recently Bouatra et al.15a collated and critically evaluated the
existing information on human urine to establish a compre-
hensive and electronically accessible human urine metabolome
database (http://www.urinemetabolome.ca). This database
includes quantitative concentrations of metabolites in normal
and abnormal (i.e., disease-associated) urine samples and
represents a significant development and resource for biomarker
identification and quantification. This database also serves as a
benchmarking and cross-referencing tool for future meta-
bolomics approaches and will no doubt aid in efforts aimed at
standardizing metabolomic approaches. While it is impractical to
cover all biomarker examples described in the human urine
metabolome database, it is perhaps useful to highlight some of
the studies where NMR-basedmetabolomics was used to identify
novel or potentially important biomarkers in urine. These are
summarized in Table 2 and explained in more detail below.
As can be seen in Table 2, urinary biomarkers have been
identified for a wide range of conditions, ranging from cancer to
neonatal conditions to pancreatic disorders. For example,
Lusczek and colleagues identified a useful set of potentially
discriminating metabolites in the urine of pancreatitis patients
compared with healthy controls.61 Although the metabolites
identified in this study cannot be conclusively defined as bio-
markers of the disease, they do have the potential to become
biomarkers once additional studies are carried out to validate
their findings, ideally using a larger patient cohort. In a similar
study aimed at exploring other kinds of pancreatic disorders,
Davis et al. used NMR-based metabolomics investigation on
urine samples from age- and gender-matched patients with
pancreatic ductal adenocarcinoma, compared with a healthy
control group.76 These authors were able to easily differentiate
between those with cancer and those in the control group (using
both ROC curves and area under the curve [AUROC]
calculations) using the set of strongly diagnostic metabolites
listed in Table 2. As with the previous study, further validation
using a larger cohort is needed to confirm the result. In another
cancer-based study, urinary 1H NMR spectra of bladder cancer
patients versus noncancer controls (healthy and those with
urinary tract infections or bladder stones) were used to discri-
minate between the two groups, with taurine showing significant
elevation in the urine of bladder cancer patients;62 however, the
authors of this study were not able to discriminate between
different disease stages possibly due to cancer-specific metabolic
alterations or the low sensitivity of their particular instrument.62
Urinary biomarkers were also used to successfully and accurately
diagnose a cohort West African patients with hepatocellular
carcinoma.63 In this particular study the authors not only
calculated ROC and AUROC values, they actually validated their
findings using second larger cohort, a very good practice indeed.
The metabolite biomarker panel identified in this study was also
shown to perform much better than serum alpha-fetoprotein, a
protein biomarker that is traditionally used for hepatocellular
carcinoma diagnosis.63
Another interesting set of studies highlighted in Table 2
concerns the application of NMR-based urinary metabolomics to
neonatal diagnoses. One very interesting NMR-based study used
urine samples from neonates to compare those with intrauterine
growth retardation versus full-term normal-weight controls
to better define the metabolic patterns associated with this
pathology. The authors identified myo-inositol, sarcosine,
creatine, and creatinine as key metabolites that clearly differ-
entiated between the two groups.64 While the initial findings are
promising, the results will need to be further validated on a larger
cohort. A more recent study on influence of early nutritional
metabolic programming and long-term health in infants was
carried out by Moltu et al. using NMR-based urinary meta-
bolomics. In this intervention study, one group received
significantly higher amounts of enhanced postnatal nutrition
compared with the control group. We concluded that the
Journal of Proteome Research Reviews
DOI: 10.1021/acs.jproteome.5b00885
J. Proteome Res. 2016, 15, 360−373
366
enhanced nutrition did not appear to affect the urinary profiles
to an extent exceeding the individual variation.65 This particular
study is a good example of a well-conducted nutritional
intervention study.
While the list of examples highlighted here (and in Table 2) is
not exhaustive, it does highlight some of the common issues and
challenges with respect to designing, implementing, and
validating NMR-based urinary metabolomic biomarker studies.
On the basis of these examples as well as an extensive review
of the literature and a detailed assessment of the best practices
conducted in our own laboratories and elsewhere, we have
developed a set of consensus recommendations. These are
summarized below.
6. RECOMMENDATIONS FOR SAMPLE COLLECTION
AND PROCESSING
The identification of new biomarkers, along with their validation
and translation into practical clinical applications, requires
standardized preanalytical procedures for sample handling,
sample stabilization, sample transport, and sample storage.
Depending on the procedures employed, the detectable
metabolites may be affected differentially by residual enzymatic
activities or spontaneous chemical reactions that may alter the
NMR profile.66 These alterations could seriously bias the results
of studies based on samples having different collection,
treatment, and storage histories. Other factors that may affect
the concentration levels of urine metabolites include drug
administration, health conditions, diet, physical activities, and
environmental stressers. Thus, it is crucial for any quantitative
urinary analysis to standardize sample collection conditions.
Our recommendations are as follows:
Overnight Fasting
Overnight fasting prior to urine collection gives a more stable
homeostatic picture of an individual’s urinary metabolome.
Consequently, we recommend that all urine samples should be
collected the morning after overnight fasting to reduce the effects
of diurnal variations.67
Midstream Urine
Collecting midstream urine is recommended to avoid contami-
nation from epithelial cells and bacteria from the urinary tract.
Sampling conditions should be similar in control groups including
age- and gender-matched groups for comparative analysis.
Medical Procedures
Medical procedures (including drug intake) performed before
sample collection should be recorded and properly taken into
account as medical treatments could induce significant changes
in metabolites levels. All medical procedures prior to sample
collection should be reported.
Aliquoting, Centrifugation, and Filtering Prior to Storage
Urine samples should be processed and aliquoted within 2 h from
the time of collection but preferably faster. Samples must be kept
refrigerated at 4 °C before processing and must not be frozen
prior to processing to avoid possible cell breakage.20d Before
aliquoting and long-term storage, urine samples should be
centrifuged at 1000−3000 RCF (5 min at 4 °C) and (optionally)
filtered using a 0.22 μm filter20d to remove cells and other
particulates.
Storage
For long-term storage, urine samples should be stored at−80 °C.
If possible, for very long-term storage, it is better to use liquid
nitrogen vapor.20d Appropriately labeled cryovials should be used
to store urine samples.
Preservatives
The addition of micromolar quantities of inorganic bacteriostatic
agents such as sodium azide (to limit bacterial growth) is
appropriate. The use of externally added organic preservatives
(such as EDTA or glycerol) is strongly discouraged due to their
possible interference with metabolite signals.
Diet Monitoring
Certain metabolites may be affected significantly by dietary
intake. If possible, dietary information should be collected for
1 to 2 days before sampling. For example, taurine increases
significantly after the consumption of taurine containing diet and
energy drinks.68 To reduce lifestyle-related variations, and to the
extent experimental design allows, a standardized diet is
recommended for donors at least 1 day before sample collection.
Native Samples
Performing urine metabolomics on native (unadulterated,
unprocessed) samples provides more reproducible and precise
data. Extraction procedures, along with multistep sampling
processes, increase the chance of metabolite loss. They also
introduce analytical and operator errors.20d,69
Buffering
An example basic protocol would be to mix 630 μL of human
urine with 70 μL of phosphate buffer (prepared in 2H2O) to
minimize the drift in chemical shift due to pH variations.
A concentrated KH2PO4 solution (1.5 M, pH 7.0) is best.
If the variation in pH between the samples is still significant after
the addition of the phosphate buffer, sample pHmay be adjusted
by adding NaOH or HCl accordingly.15b
Final Centrifugation
Centrifugation at 12 000g for at least 10 min at 4 °C to remove
any suspended particles is strongly encouraged.20d
Chemical Shift Referencing
A chemical shift referencing standard such as TSP or DSS should
always be added prior to NMR collection. Because the peak
is easily resolved and unique, chemical shift standards can also
be used for metabolite quantification. Note that DSS and TSP
do bind proteins and lipids, so if these macromolecules are
present to any significant degree, they may give rise to errors in
quantitation. A final TSP or DSS concentration ranging between
0.1 and 0.5 mM is sufficient for most urine samples.
7. RECOMMENDATIONS FOR SPECTRAL ACQUISITION
AND PROCESSING
In addition to the recommendations for spectral acquisition that
have been proposed in our previous reference paper,22 there
are a number of instrumental, acquisition, and data-processing
parameters that can significantly affect quantitative accuracy and
precision. These parameters need to be optimized prior to
conducting quantitative analysis of urine samples. Here we
provide recommendations and justifications related to these
issues.
7.1. Acquisition of Urinary NMR Data
Selection of Magnetic Field. NMR-based metabolomics
studies on urine benefit from the use of the highest accessible
magnetic field strengths. Presently, most NMR-based metabo-
lomic studies are conducted using 600 MHz NMR spectrom-
eters, as these instruments are relatively abundant and offer a
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good compromise between the cost, sensitivity, and resolution
needed for metabolomics experiments. If the purpose of the
analysis is the quantification or the identification of low
abundance metabolites, we recommend using more sophisti-
cated 2D experiments, higher fields (e.g., 800−1000 MHz), or
increased sensitivity “cold-probes” or “cryoprobes”.
Pulse Sequence and General Setup. Automated pulse
width calibration70 is strongly recommended for anyNMR-based
metabolomic study of urine. This is because urine samples exhibit
considerable variability in salt concentrations, which substantially
affect pulse widths. Pulse width calibration also helps to
compensate for differences in sample volume or drift/decay in
NMR hardware performance. For example, if components of the
spectrometer or probe begin to fail, then pulse width calibrations
will immediately indicate a problem and prevent wasted time and
resources. Most modern NMR spectrometers have the option of
sample handling robots for sample insertion into the spec-
trometer. Most NMR instruments also support autopulse
calibration, autoshim, and auto tune/match prior to data
acquisition. If available, these automated approaches should be
used for all urine-based metabolomics studies to reduce human
error and ensure maximum consistency and reproducibility.
Water Suppression. As previously detailed, a 1D NOESY
pulse sequence with water presaturation, is the most commonly
used NMR pulse sequence for metabolomics studies. While
there are other excellent solvent suppression techniques such as
excitation sculpting, or WATERGATE, the incorporation of
pulsed field gradients can easily result in inconsistent
spectrometer lock performance, the introduction of artifacts,
and irreproducible solvent suppression; however, a presaturation
pulse if done inconsistently, can also dramatically alter quanti-
tation results due to hydrogen exchange with the solvent during
the long saturation period(s).71 We therefore strongly
recommend the use of an absolutely consistent presaturation
period (e.g., 1 s) with equally consistently delivered and
calibrated power (e.g., 80 Hz gamma B1 induced field). Of
note, the exchangeable hydrogen signal from urea’s NH2- groups
and other water exchangeable signals can also be suppressed by
time-shared multifrequency saturation-based sequences,72 but
these also introduce additional regions of suppression that can
alter quantitation. Therefore, these types of sequences are not
recommended for metabolomics.
Sample Temperature Control. Variations in the sample
temperature during spectral acquisition can significantly affect
the precision and reproducibility of NMR data. A calibrated
sample temperature of ∼298 K (25 °C) for urine is recom-
mended during NMR spectral acquisition. If a robotic sample
handling system is being used, where large numbers of samples
are prepared in advance and stored at the instrument, the samples
should be kept below room temperature (∼ 5 °C) while waiting
for sample insertion.29a,73 Samples should be prewarmed outside
or in the probe for 5−10 min before spectral acquisition to
ensure proper temperature equilibration, especially if a cooling
rack is used to maintain refrigerated samples. While samples will
begin to show thermal equilibrium via lock monitoring in 60 to
120 s, several minutes of equilibration are often necessary for
convection currents to settle.
NMR Tubes. Higher quality NMR tubes yield higher quality
spectra. Therefore, we recommend that the highest quality tubes
with the lowest camber (straightest), thinnest, most consistent
glass wall widths be used. Slightly curved tubes will wobble while
spinning, which can lead to spinning side bands (extra peaks).
Most NMR spectroscopists use 5 mm tubes, requiring volumes
of 400−600 μL of material. If less material is available, the use
of 3 mm or even 1.7 mm tubes is possible. Likewise, solvent-
matched (Shigemi) tubes may also be used for low volume
situations; however this option can increase the cost significantly.
Prior to their use, NMR tubes should be cleaned to remove any
film. Cleaned tubes tend to sheet refluxed material back down
into the bottom of the tube, thus reaching equilibrium faster.
Dirty or stock tubes with the film remaining from manufacturing
will bead solvent further up the tube, effectively shortening the
sample length and changing the magnetic field homogeneity.
7.2. Recommendations for Optimized Instrumental
Parameters
Time Domain Points (Bruker TD or Agilent np).Modern
NMR spectrometers with high-speed/high-memory computers
and digital oversampling can easily collect 64K or more data
points. Considering the expected spectral windows and the
desired resolution for NMR-based metabolomics work, time
domain acquisitions ≥32K points are recommended for
quantitative analysis of urine samples.
Repetition Time (TR). This is also known as the relaxation
delay or waiting period prior to the first hard excitation pulse.
We define this period as the total time spent in acquiring a single
scan spectrum, including the acquisition time and acquisition
delays prior to the next excitation/acquisition. This period
strongly affects the absolute quantitation of metabolites. Ideally,
TR should be five times the longest T1 in the sample. This
typically provides enough time for complete relaxation of all
resonances between every scan, resulting in good quantitation.
In metabolomics studies, using a TR that is five times the longest
T1 in a sample requiring 128 scans would result in a sacrifice of
enormous amounts of instrumental time that would dramatically
increase the cost of the overall study. As a result, a shorter
repetition time (e.g., 2−4 s) is often used for many NMR
studies.69 The key is that the total relaxation time used is
consistent from experiment to experiment. For absolute
quantitation of metabolites, a T1 correction factor for spectra
recorded over a shorter TR time can be determined and applied
to compensate for the effect of incomplete relaxation.74 Appli-
cation of this correction requires evaluation of the T1 for all
resonances of interest in a representative sample prior to
quantitation, assuming that theT1 of the resonances would be the
same in all samples for the study. Alternately, using reference
spectra of compounds of known concentration that have been
collected using the same TR and using these reference spectra to
deconvolute the mixture (as done with Chenomx, AMIX,
Batman, or Bayesil) would also allow one to accurately determine
concentrations.
Number of Scans/Signal to Noise Ratio. The better the
signal-to-noise (S/N) is for a NMR spectrum, the more reliable
the absolute quantitation. The simplest way to increase (S/N) in
NMR is to increase the number of scans (also known as
transients); however, adding more scans must be balanced by
cost or time considerations. The S/N also depends on other
factors like the magnetic field strength, stability of the
spectrometer, probe type/quality, sample concentration, sample
volume, excitation flip angle, and so on. If time and resources
permit, maximizing each of these factors (field strength, stability,
probe quality, sample concentration, sample volume, and flip
angle) will yield significant gains in S/N without the need for
additional acquisition time. Thirty-two to sixty-four scans
are often considered enough for a normal urine sample on a
600 MHz (or greater field strength) instrument. Dilute urine will
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require more scans to achieve the desired S/N for quantitative
NMR analysis. More scans (or higher fields) are also required to
detect and quantify minor components (<10 uM) in urine or
very dilute samples. Use of a cryogenically cooled probe can
significantly (by a factor of 2−4 times) increase the S/N for the
sample.
Receiver Gain (RG). NMR experiments can be run either on
a constant receiver gain setting (optimized to a standard sample)
or with an automatically optimized receiver gain for every
sample. The former is preferred for pattern recognition analysis
of urine NMR data; however, it does not work on samples where
concentration variation between samples is substantial. In these
cases the auto receiver gain setting may be required for every
sample prior to acquisition, or an efficiently low gain would be
required.
Shimming. Automatic shimming options in newer NMR
spectrometers have made shimming much easier and faster for
metabolomic analysis. NMR shims can be optimized by watching
the line shape and width at half-height of the reference signal
(such as DSS or TSP) or another common low-molecular-weight
component. For DSS/TSP, observing the intensity and
symmetry of the silicon (29Si) satellite signal is also a good
option to optimize the shimming process. The line width of
chemical shift standards such as DSS or TSP should be shimmed
to between 0.5 and 1.0 Hz. Adjustment of the field and lock
position/phase during the shimming process can also improve
the quality of the spectra.
Tuning and Matching. Probe tuning and matching (which
is equivalent to tuning a radio) are essential to getting high-
quality NMR spectra. Many NMR instruments are tuned for
salt-free solvents (chloroform or D2O); however, buffered urine
samples typically have high salt concentrations. This can lead to
poor performance (low S/N, long pulses, poor solvent
suppression, etc.) on high-field NMR spectrometers that have
not previously been tuned to accommodate high salt samples.
These difficulties can become more evident when a user is
acquiring data on a cryogenically cooled NMR probe. Ideally,
manual probe tuning and matching for a given sample or solvent
type (using a representative sample) should be performed prior
to spectral acquisition for a large number of solvent-similar
samples. Autotune capabilities and match accessories along with
salt tolerant NMR flat sample tubes can help mitigate this
problem.
7.3. Data Processing
Proper data processing can improve the S/N, resolution, visual
appearance, and the integration accuracy of 1D NMR spectra.
Several simple data processing techniques may be employed,
some of which are automatic while others require some manual
effort and skill. Our recommendations are as follows:
Windowing or Apodization. A window function should be
applied to the time domain data prior to Fourier transformation
to improve the appearance of the spectra and emphasize either
S/N or resolution (both are not possible). In a urine 1D
spectrum, a free induction decay (FID) can be multiplied by an
exponential window function. The artificially increased decay
rate of an exponential windowing function (which minimizes
later time points in the FID) will reduce the noise and broaden
the resonance lines. On the contrary, a window function that
enhances later time points in the FID will enhance resolution but
at the expense of increasing spectral noise. Line broadening
between 0.3 and 1.0 Hz is recommended for quantitative analysis
of urine samples. The exact value will depend on the digital
resolution of the experiment. Line broadening equal to the digital
resolution is generally recommended, as it provides no penalty
in spectral separation but does improve general spectral
appearance.
Zero Filling. FID data should be zero-filled by a factor of 2
(i.e., twice the number of experimentally collected data points)
before Fourier transformation to reduce noise and improve the
visual appearance of the spectra. Zero filling does not increase the
actual spectral resolution but functions to better interpolate
between real data points in the original spectrum, thereby
improving line-fitting and peak position determination. While
often over emphasized, zero filling is still helpful for many NMR
spectroscopists and does not require additional spectrometer
time. Extending zero filling past a factor of 2 does little for
the spectra, takes up more storage space, and slows software
calculations.
Phasing. Phasing is one of the most critical yet one of the
more error-prone steps in performing quantitative NMR. Errors
in phasing can cause significant errors in absolute and relative
peak area measurements.75 Manual phasing is preferred over
automatic phasing because there is a greater chance of distortion
among lower intensity signals during automatic phase correction.
Vertical expansion should be increased as much as possible
during manual phasing to make the proper adjustments for
smaller signals. Water peaks can be ignored during phasing, and
the water signal should be removed (through postprocessing
digital filtration) from the spectra to enable further qualitative
and quantitative analysis. Experimental errors in the pulse
sequence can often manifest as apparent “phase” distortions
but cannot be corrected with either frequency-dependent or
frequency-independent corrections. Dispersive peak character-
istics, especially on very intense peaks, should be carefully
examined and noted in case the NMR parameters/setup need to
be altered.
Base Line Correction. Proper baseline corrections are
necessary for quantitative accuracy of peak integration and curve-
fitting methods applied to calculate peak areas. Most baseline
corrections are performed semiautomatically through manual
identification of baseline regions, followed by a computer-
generated spline fit to the baseline regions. Several third-party
software packages can also perform automated baseline
correction.50
Chemical Shift Referencing. Every spectrum needs to be
properly referenced to an internal chemical shift standard before
qualitative/quantitative analysis. In many cases, because the
precise concentration of the standard is known, the chemical shift
standard can also be used to determine the concentration of
other compounds by comparing the relative peak areas. Both
trimethylsilyl propanoic acid (TSP) and 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) can be used for chemical
shift referencing in water (δ 0.0), although DSS is the IUPAC
standard. While other peaks may be used in place of an internal
standard if they are very insensitive to pH/ionic strength
variations, this practice is definitely not recommended for most
applications (water has been successfully used as a concentration
reference).52 Chemical shift referencing to solvent peaks
(i.e., water) should be avoided because its peak position is
sensitive to pH, salt, and temperature effects.
■ CONCLUDING REMARKS
Despite the growing number of publications focused on
diagnostic metabolite biomarkers appearing in the scientific
literature, a surprisingly small number of these reports provide
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information on quantified metabolite levels, especially in urine.
This situation indicates that metabolite identification and
quantification in urine is still considered a challenging task.
For metabolite biomarkers, accurate identification and quanti-
fication is essential for advancing biomarker discoveries to
clinical practice. As noted throughout this review, NMR
spectroscopy offers a robust route to the identification and
quantification of metabolites. In this regard, we believe
quantitative NMR-based metabolomics represents a superb
(albeit under-used) platform for the discovery, development, and
translation of metabolite biomarkers to clinical practice. In this
Review, we focused on the use of urine as a biofluid for biomarker
discovery and biomarker applications. In particular, we explained
how biomarkers should be evaluated or assessed. We also
elaborated on several methods for metabolite identification,
quantification and normalization by NMR and provided
examples of a number of newly discovered urinary metabolite
biomarkers. We further discussed a number of the most signi-
ficant issues or challenges regarding the experimental aspects of
quantitative, NMR-based urinary metabolomics. To address
these experimental challenges, several consensus recommenda-
tions were provided. These included best-practice recommen-
dations regarding: (1) sample collection, (2) sample processing
and storage, (3) NMR data acquisition, and (4) NMR instru-
ment setup and NMR data processing. Detailed justifications
were provided for each of these recommendations. We believe
that if these recommendations are followed, they will help
members of the NMR metabolomics community better validate
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